GADD45A plays a protective role against temozolomide treatment in glioblastoma cells
Abstract Glioblastoma multiforme (GBM) is one of the most aggressive cancers. Despite recent advances in multimodal therapies, high-grade glioma remains fatal. Temozolomide (TMZ) is an alkylating agent used worldwide for the clinical treatment of GBM; however, the innate and acquired resistance of G...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2017-08-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-06851-3 |